Trial reportSignal transduction and targeted therapy2024
Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.
Abstract readClinical Trial
In one paragraph
Trial report in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Pathway-specific mechanisms, therapeutic applications, and toxicodynamic profile of acriflavine in cancer: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Mutant-Selective Binding ofInternational journal of molecular sciences · 2026Article
- COLEC12high tumor-associated macrophages: A novel paracrine axis driving lenvatinib resistance in hepatocellular carcinoma: Editorial on "COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling".Clinical and molecular hepatology · 2026Article
- A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations.Journal of gastrointestinal oncology · 2026Article
- Exploring Microalgae as a Novel Resource for Hepatocellular Carcinoma Therapy.Molecules (Basel, Switzerland) · 2026Review
- SPP1+ Macrophages and the Orchestration of Spatially Organized Immunosuppression in Cancer.Biomedicines · 2026Review
- Structure-Based Virtual Screening for KHK-A Inhibitors with Anti-Hepatocellular Carcinoma Activity.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Charting the Clinical Landscape of Lenvatinib-Integrated Therapies for Hepatocellular Carcinoma.Annals of surgical oncology · 2025Article
- Kuwanon A Targeted YWHAB in Hepatocellular Carcinoma Cells to Inhibit the Raf/MEK/ERK Signaling Pathway.Cells · 2025Article
- Molecular profiling of circulating tumor cells guides effective EGFR inhibitor treatment in advanced hepatocellular carcinoma: a case report.Frontiers in oncology · 2025Article
- Nanomaterials for liver cancer targeting: research progress and future prospects.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Yaoping Shi *Department of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. shi_yaoping@163.com.
Dan Cui *Department of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Lei Xia *Department of Liver Surgery, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Donghua ShiDepartment of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Guangxin JinDepartment of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Siying WangShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Yan LinDepartment of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Xiaoyin TangDepartment of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Jiachang ChiDepartment of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Tao WangDepartment of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Meng LiDepartment of Liver Surgery, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Zicheng LvDepartment of Liver Surgery, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Jiaojiao ZhengShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Qi JiaShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.ORCID 0000-0002-0769-1874
Wu YangShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.ORCID 0000-0002-6782-0439
Zhen SunShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Fan YangDepartment of Pharmacy, Renji Hospital, Shanghai Jiao Tong University, Shanghai, PR China.
Hao FengDepartment of Liver Surgery, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Shengxian YuanThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital, Naval Medical University, Shanghai, PR China.
Weiping ZhouThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital, Naval Medical University, Shanghai, PR China.
Wenxin QinShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. wxqin@sjtu.edu.cn.ORCID 0000-0002-1989-3027
Rene BernardsShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. r.bernards@nki.nl.ORCID 0000-0001-8677-3423
Haojie JinShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. hjjin1986@126.com.ORCID 0000-0001-9295-1951
Bo ZhaiDepartment of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. zhaiboshi@sina.com.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lenvatinib, a multi-kinase inhibitor, has been approved as first-line treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is limited. We have shown previously that lenvatinib and epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) combination therapy overcomes lenvatinib resistance in HCC with high level of EGFR expression (EGFR
Indexed as
Carcinoma, HepatocellularDrug Resistance, NeoplasmGefitinibLiver NeoplasmsPhenylurea CompoundsQuinolinesAdultAgedAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsFemaleHumansMaleMiddle AgedProspective StudiesEGFR protein, humanErbB ReceptorsGefitiniblenvatinibPhenylurea CompoundsQuinolines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.